**Supplementary Fig. 4** Ado/A2AR impact p-CREB and TCR signaling activation. (**a**) Representative example of p-CREB expression detected by flow cytometry in total CD8+ T cells after treatment with Ado or the indicated combination of A2AR agonist (CGS 21680) and antagonist (ZM 241385) or the PKA inhibitor (KT570). (**b**) Representative western blot analysis of p-CREB and CREB in total CD8+ T whole-cell lysates after treatment with Ado or the depicted combination of A2AR antagonist (ZM 241385) or the PKA inhibitor (KT570). α-Tubulin was detected as a loading control. *n* = 3. (**c**) Cumulative data showing the fold change in p-CREB expression by distinct memory CD8+ T cell subsets (TCM, TEM, TEMRA) in presence of Ado or the A2AR selective agonist CGS 21680. The 25th to 75th percentiles, the median and min-max of the values are represented; *n* = 7. \**P* < 0.05, \*\**P* < 0.01, \*\*\**P* < 0.001, one-way ANOVA test. (**d**) Representative western blot analysis and (**e**) cumulative data of p-ERK and ERK in total CD8+ T whole-cell lysates after treatment with Ado and stimulated for 3h by anti-CD3/anti-CD28 coated beads or the depicted combination of A2AR antagonist (ZM 241385) or the PKA inhibitor (KT570). α-Tubulin was detected as a loading control. *n* = 3.